EGFR and head and neck squamous cell carcinoma: Although EGFR is overexpressed in over 90% of HNSCC cases, traditional treatments, such as cetuximab (a monoclonal antibody) and tyrosine kinase inhibitors (TKIs), have shown limited clinical efficacy, largely due to low EGFR mutation rates, acquired resistance, and the activation of alternative oncogenic pathways.